CD147-mediated chemotaxis of CD4+CD161+ T cells may contribute to local inflammation in rheumatoid arthritis
CD161 is used as a surrogate marker for Th17 cells, which are implicated in the pathogenesis of rheumatoid arthritis (RA). In this study, we evaluated the percentage, clinical significance, and CD98 and CD147 expression of CD4+CD161+ T cells. The potential role of CD147 and CD98 in cyclophilin A-induced chemotaxis of CD4+CD161+ T cells was analyzed. Thirty-seven RA patients, 15 paired synovial fluid (SF) of RA, and 22 healthy controls were recruited. The cell populations and surface expression of CD98 and CD147 were analyzed by flow cytometry. Spearman’s rank correlation coefficient and multiple linear regression were applied to calculate the correlations. Chemotaxis assay was used to investigate CD4+CD161+ T cell migration. We found that the percentage of CD4+CD161+ T cells and their expression of CD147 and CD98 in SF were higher than in the peripheral blood of RA patients. Percentage of SF CD4+CD161+ T cells was positively correlated with 28-Joint Disease Activity Score (DAS28). CD147 monoclonal antibody (HAb18) attenuated the chemotactic ability of CD4+CD161+ T cells. An increased CD4+CD161+ T cell percentage and expression of CD147 and CD98 were shown in RA SF. Percentage of SF CD4+CD161+ T cells can be used as a predictive marker of disease activity in RA. CD147 block significantly decreased the chemotactic index of CD4+CD161+ cells induced by cyclophilin A (CypA). These results imply that the accumulation of CD4+CD161+ T cells in SF and their high expression of CD147 may be associated with CypA-mediated chemotaxis and contribute to local inflammation in RA.
KeywordsCD147 CD4+CD161+ T cells CD98 Chemotaxis Rheumatoid arthritis
All research materials used in this study were provided by the Institute of Rheumatism and Immunity, Department of Clinical Immunology at Xijing Hospital. This research was supported by the National Natural Science Foundation of China (No. 81401338) and was approved by the Ethical Standards Committee of Xijing Hospital (reference number: KY20163014-1). The authors received funds to covering the costs of publishing this article. The authors also wish to thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.
Compliance with ethical standards
The study was approved by the ethics committee of Xijing Hospital, and written consent was provided by the participating patients.
- 5.Chalan P, Kroesen BJ, van der Geest KS, Huitema MG, Abdulahad WH, Bijzet J, Brouwer E, Boots AM (2013) Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis. PLoS One 8:e79370CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Miao J, Zhang K, Qiu F, Li T, Lv M, Guo N, Han Q, Zhu P (2015) Percentages of CD4+CD161+ and CD4-CD8-CD161+ T cells in the synovial fluid are correlated with disease activity in rheumatoid arthritis. Mediat Inflamm 2015:563713Google Scholar
- 21.Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CR, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRefPubMedGoogle Scholar
- 36.Cosmi L, Cimaz R, Maggi L, Santarlasci V, Capone M, Borriello F, Frosali F, Querci V, Simonini G, Barra G et al (2011) Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 63:2504–2515CrossRefPubMedGoogle Scholar
- 37.Dawar FU, Wu J, Zhao L, Khattak MN, Mei J, Lin L (2017) Updates in understanding the role of cyclophilin A in leukocyte chemotaxis. J Leukoc BiolGoogle Scholar
- 39.Gernez Y, Tirouvanziam R, Nguyen KD, Herzenberg LA, Krensky AM, Nadeau KC (2007) Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids. J Allergy Clin Immunol 120:1441–1448CrossRefPubMedPubMedCentralGoogle Scholar